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Symptoms of rheumatoid arthritis (RA) improve during pregnancy, a phenomenon 
that was found to be associated with N-glycosylation changes of immunoglobulin G. 
Recent advances in high-throughput glycosylation analysis allow the assessment of the 
N-glycome of human sera as well. The aim of this study was to identify new protein 
N-glycosylation properties that associate with changes in RA disease activity during 
and after pregnancy. A longitudinal cohort of serum samples was collected during 285 
pregnancies (32 control individuals and 253 RA patients). Per individual one sample was 
collected before conception, three during pregnancy, and three after delivery. Released 
serum protein N-glycans were measured by matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF-MS) after employing chemical modifica-
tion of the sialic acids to allow discrimination of sialic acid linkage isomers. Serum protein 
N-glycosylation showed strongly modified during pregnancy, with similar changes visible 
in control individuals and RA pregnancies. Namely, a decrease in bisection and an 
increase in galactosylation in diantennary glycans were found, as well as an increase 
in tri- and tetraantennary species and α2,3-linked sialylation thereof. The change in RA 
disease activity [DAS28(3)-CRP] proved negatively associated with the galactosylation of 
diantennary N-glycans, and positively with the sialylation of triantennary fucosylated spe-
cies (A3FGS). While the protein source of the novel finding A3FGS is thus far unknown, 
its further study may improve our understanding of the etiology of RA disease severity.
Keywords: rheumatoid arthritis, pregnancy, disease activity score 28 c-reactive protein, glycosylation, total 
serum protein N-glycosylation, ethyl esterification matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry
inTrODUcTiOn
Rheumatoid arthritis (RA) is a prevalent autoimmune disease affecting up to 1% of the adult 
population in developed regions (1, 2). Its main characteristic is a symmetrical polyarthritis 
involving predominantly the hand and foot joints, although every organ system may be involved. 
The disease is more frequently diagnosed in women than in men and is more common with 
FigUre 1 | Schematic overview of glycosylation traits derived from human 
serum proteins. N-Glycan structures are generalized into high-mannose type 
(M), hybrid type (Hy), and complex type (C) by the number of mannoses 
(green circle) and antennary N-acetylglucosamines (blue square). High-
mannose-type N-glycans can have up to nine mannoses, whereas each 
antennary N-acetylglucosamine can be terminally substituted with a 
galactose (yellow circle), and sialic acid (magenta diamond). Sialic acids (S) 
can either be α2,3-linked (L) or α2,6-linked (E). N-Glycans can further be 
modified with a fucose (F), optionally at an antennary N-acetylglucosamine 
(Fa), and structures may as well be bisected (B). In case of derived traits, the 
subject of the calculation is represented by the last letter, e.g., sialylation (S), 
and the group on which it is calculated by the preceding letters, e.g., 
triantennary fucosylated species (A3F). This, for instance, translates A3FGS 
into the sialylation per galactose within triantennary fucosylated species.
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increasing age (1, 3). The potential causes of RA are diverse in 
nature (4, 5), but a role for T-cells, antibody-producing B-cells, 
but also monocytes/macrophages has been suggested (1, 6). 
Interestingly, in many female RA patients, an improvement in 
RA disease severity is reported during pregnancy, as well as 
a relapse thereof after delivery (7–10). The reasons for these 
changes in disease activity are still poorly understood, but are of 
importance to understand the etiology of RA, and may possibly 
provide leads for new modes of (personalized) treatment.
Glycosylation, the process of co- and posttranslational protein 
modification with complex carbohydrates, plays an important role 
in the interaction, function, and solubility of proteins (11–13). 
It is expected that more than half of all proteins is glycosylated 
with one or more N-glycans (14), and commonly observed gly-
coforms range from high-mannose- to complex type with two 
to four antennae (branching N-acetylglucosamines) (Figure 1) 
(12, 15). These structures may be extended by additional mono-
saccharides such as a bisecting N-acetylglucosamine, as well as 
galactoses, N-acetylneuraminic acids (sialic acids), and fucoses 
in a variety of different positions and linkages. This leads to a 
large N-glycan diversity, and may also lead to the formation of 
specific epitopes such as sialyl-Lewis X, which can be recognized 
by E-selectin (12, 16).
Various proteins have already been found to display altered 
glycosylation with RA and its disease activity. For instance, the 
N-glycosylation of the fragment-crystallizable (Fc) portion of 
immunoglobulin G (IgG) shows to differ in galactosylation, 
bisection, and fucosylation (17–23), and the acute-phase protein 
alpha-1-acid glycoprotein (also known as orosomucoid) shows 
differences in antennarity (i.e., the ratio between di-, tri-, and 
tetraantennary glycans) and fucosylation with RA as well as 
changes throughout pregnancy (24, 25). Although such an analy-
sis of single proteins is highly informative, additional insights 
may be gained by a systemic glycomics approach that covers a 
broad range of protein-linked glycan modifications.
The total serum N-glycome (TSNG) comprises the N-glycans 
from all serum proteins, which are to a large extent liver- (acute-
phase proteins) and plasma cell-derived (antibodies) (15, 26). 
Interestingly, the TSNG has been shown, in a small sample set, 
to differ between healthy individuals and those with RA, and 
undergoes clear alteration throughout pregnancy and the follow-
ing postpartum period (27, 28). However, it is hitherto unknown 
which TSNG characteristics are associated with the disease 
activity of RA, and changes thereof throughout pregnancy. 
Recent developments in mass spectrometry (MS)-based high-
throughput glycosylation analysis have provided the opportunity 
to acquire information on TSNG N-glycan complexity, anten-
narity, galactosylation, fucosylation, as well as on the presence 
and linkage of sialic acids (α2,6- vs. α2,3-linkage) (29, 30). The 
latter appears to be of high immunological relevance, since the 
α2,3-linked sialic acids are required for sialyl-Lewis X formation 
implicated in the interaction with selectins (29, 30).
The objective of the work presented here is to assess the dif-
ferences in serum N-glycosylation throughout pregnancy and the 
postpartum period in RA patients and to identify the glycosyla-
tion properties associated with the changes in disease activity 
[DAS28(3)-CRP] during pregnancy. To achieve this, we studied 
the N-glycosylation of sera from 253 RA and 32 control preg-
nancies at seven time points before, during, and after pregnancy 
by matrix-assisted laser desorption/ionization time-of-flight 
(MALDI-TOF) MS and report the disease- and pregnancy-
associated changes of 78 N-glycan species and 91 glycosylation 
traits derived thereof.
MaTerials anD MeThODs
study Population and sample collection
The current research is embedded in the PARA study, a nation-
wide prospective cohort on pregnancy and RA (21, 31). The 
cohort consisted of serum samples of 253 pregnancies from 219 
RA patients, collected between 2002 and 2009 (31). In addition, 
32 pregnancies of healthy Caucasian volunteers without adverse 
obstetric histories were included and followed from the first 
trimester of pregnancy. Of each patient, at least one sample 
was obtained during pregnancy and one postpartum, with a 
minimum of three samples per patient. Only completed preg-
nancies were included and all patients fulfilled the 1987 ACR 
criteria for RA. Disease activity was assessed using the disease 
activity score (DAS) in 28 joints, incorporating the swollen joint 
count, the tender joint count and the C-reactive protein (CRP) 
level [DAS28(3)-CRP]. The study was in compliance with the 
Helsinki Declaration and was approved by the Ethics Review 
Board at the Erasmus University Medical Center, Rotterdam, the 
Netherlands. Written and informed consent was obtained from 
all research participants included in this study. For quality con-
trol purposes, 111 plasma standards (Visucon-F frozen normal 
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control plasma, pooled from 20 human donors, citrated, and 
buffered with 0.02 M HEPES, obtained from Affinity Biologicals, 
Ancaster, ON, Canada) and 40 PBS blanks were distributed 
across the 21 96-well sample plates.
chemicals and enzymes
SDS and analytical grade ethanol were obtained from Merck 
(Darmstadt, Germany). Disodium hydrogen phosphate dihy-
drate (Na2HPO4  ×  2H2O), potassium dihydrogenphosphate 
(KH2PO4), sodium chloride, Nonidet P-40 substitute (NP-40), 
1-hydroxybenzotriazole monohydrate 97% (HOBt), 50% sodium 
hydroxide (NaOH), and super-DHB were obtained from Sigma-
Aldrich (Steinheim, Germany). HPLC-grade acetonitrile (ACN) 
was purchased from Biosolve (Valkenswaard, the Netherlands), 
and 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide (EDC) 
hydrochloride was obtained from Fluorochem (Hadfield, UK). 
Peptide-N-glycosidase F (PNGase F) was obtained from Roche 
Diagnostics (Mannheim, Germany) and ultrapure water (MQ) 
was generated from a Purelab Ultra system (Veolia Water 
Technologies, Ede, the Netherlands), which was maintained at 
18.2 MΩ at 25°C.
enzymatic N-glycan release
N-Glycans were released from serum proteins using PNGase F, as 
was previously described (32). In summary, 6 µL serum of each 
sample was denatured by addition of 12 µL of 2% SDS, followed 
by incubation for 10 min at 60°C. The release step was performed 
by the addition of 12.6 µL releasing mixture, which consisted of 
2.5× PBS containing 2% NP-40 and 0.4 mU PNGase F, followed 
by 16 h incubation at 37°C. After release, the samples were stored 
at −20°C or transferred to the robot platform to be used directly.
glycan Derivatization and Purification
Further sample preparation was performed on an automated 
system, as previously described (30). In short, linkage-specific 
sialic acid stabilization (ethyl esterification) was performed by 
adding 60 µL 250 mM EDC 250 mM HOBt in ethanol to 3 µL 
released glycan sample. This mixture was incubated for 75 min 
at room temperature, after which 120  µL ACN was added. To 
purify the samples, a GHP membrane (GHP plate, Pall AcroPrep 
Advance 96 Filter plate, Pall Corporation, Ann Arbor, MI, USA) 
was prewetted with 70% ethanol, activated with MQ and equili-
brated with 100% ACN. The complete sample was transferred to 
the GHP plate and incubated for 5 min. Subsequently the GHP 
plate was washed three times with 100 µL 96% ACN. Elution was 
performed by adding 30 µL of MQ to the GHP plate, incubating 
at room temperature for 5 min, followed by centrifugation into 
a PCR plate.
Matrix-assisted laser Desorption/
ionization Time-of-Flight Mass 
spectrometry (MalDi-TOF-Ms) analysis
From each purified sample, 10  µL was premixed with 10  µL 
matrix consisting of 5  mg/mL super-DHB in 99% ACN with 
1 mM NaOH. Of this mixture, 2 µL was spotted onto a MALDI 
target plate (800/384 MTP AnchorChip, Bruker Daltonics, 
Bremen, Germany) and was left to dry. MALDI-TOF-MS spectra 
were recorded on an UltrafleXtreme mass spectrometer with a 
Smartbeam-II laser (Bruker Daltonics) in reflectron positive 
mode, controlled by flexControl 3.4 (Build 135). Measurements 
were performed within a range from m/z 1,000 to 5,000, accumu-
lating 10,000 laser shots at a frequency of 1,000 Hz and with 100 
shots per raster spot using a random walking pattern.
Data Preprocessing
Average spectra were separately created for all healthy samples 
and for all RA samples. Within these two averages, 98 signals 
were manually assigned to putatively originate from glycan com-
positions. Using flexAnalysis 3.4 (Bruker Daltonics), the spectra 
were transformed into text format (x,y). Massytools (version 
0.1.7.1 beta) was used to perform calibration and integration of 
the text files (33). Specifically, calibration was performed with a 
high precision calibration list, requiring at least 5 calibrants to 
be present at a RMS S/N ≥ 6 (119 spectra were excluded during 
this step, which included all 40 blanks). The putative glycan 
structures were extracted covering 95% of the isotopic envelope, 
summing per isotope the background-corrected area.
Spectra with quality control values below 3 SD of the mean 
values [i.e., fraction of spectrum in analytes, fraction of analyte 
area above S/N 9, and highest main peak (H5N4E2) S/N] were 
excluded from further analysis (13 spectra). Putative glycan sig-
nals were excluded from further analysis if failing to be present 
in 15% or more spectra of any analytical group (healthy, RA, 
standard) with an S/N ≥ 6 and a ppm error of at most 15 (which 
led to the exclusion of 21 signals). After curation, we retained 
1,841 spectra with 78 analytes (Table S1 in Supplementary 
Material). Single N-glycan areas were normalized to the sum 
of all areas. To prevent outlier influence on the data analysis, 
individual glycosylation values surpassing 5 SD from their 
mean were removed from further analysis (118 values). Derived 
traits were calculated from the single glycans (Table S2 in 
Supplementary Material).
Data analysis
Measurement repeatability was assessed by calculating the mean, 
SD, and CV for all glycans and derived traits within the plasma 
controls (Table S3 and Figure S1 in Supplementary Material). 
Statistical analyses were performed using R 3.1.2 in an environ-
ment of RStudio 0.98.1091 (RStudio Team, Boston, MA, USA) 
(34). Figures were annotated with glycan symbols created in 
GlycoWorkbench 2.1 following the nomenclature proposed by 
the Consortium for Functional Glycomics (35, 36). For all sta-
tistical analyses, glycosylation values were scaled and centered, 
making regression effect sizes (B) representative of a 1 SD change 
in the glycan value.
Association between glycosylation and, respectively, preg-
nancy, RA, and DAS28(3)-CRP was explored by mixed linear 
regression. To establish the effect of pregnancy on glycosylation, 
a binary time point classification was constructed between (A) 
the first and third trimesters of pregnancy (coded, respectively, 
as 0 and 1), (B) the third trimester of pregnancy and 6 weeks 
postpartum (respectively, 0 and 1), and (C) the third trimester 
of pregnancy and 26+ weeks postpartum (respectively, 0 and 1). 
Table 2 | Medication.
pc (n = 131) tm1 (n = 225) tm2 (n = 235) tm3 (n = 240) pp1 (n = 243) pp2 (n = 243) pp3 (n = 245)
Prednisone, n (%) 38/111 (34.2) 80/217 (36.9) 87/234 (37.2) 81/238 (34.0) 85/236 (36.0) 88/239 (36.8) 79/240 (32.9)
Sulfasalazine, n (%) 44/130 (33.8) 63/224 (28.1) 65/235 (27.7) 61/239 (25.5) 61/241 (25.3) 73/243 (30.0) 71/243 (29.2)
Hydroxychloroquine, n (%) 9/130 (6.9) 5/224 (2.2) 5/235 (2.1) 4/239 (1.7) 9/241 (3.7) 18/243 (7.4) 17/243 (7.0)
Methotrexate, n (%) 0/130 (0.0) 0/224 (0.0) 0/235 (0.0) 0/239 (0.0) 34/241 (14.1) 59/243 (24.3) 74/243 (30.5)
TNF-inhibitors, n (%) 5/130 (3.8) 0/224 (0.0) 0/235 (0.0) 0/239 (0.0) 13/241 (5.4) 23/243 (9.5) 29/243 (11.9)
pc, preconception; tm1, first trimester; tm2, second trimester; tm3, third trimester; pp1, 6 weeks postpartum; pp2, 12 weeks postpartum; pp3, 26 weeks postpartum.







Age at delivery in years, mean (SD) 32.1 (4.4) 32.8 (3.7)
Duration of pregnancy in weeks, mean (SD) 40.1 (1.4) 39.2 (1.9)
Disease duration at first visit in years, mean (SD) – 7.7 (6.3)
ACPA-positive patients, n (%) – 153/253 (60.5)
RF-positive patients, n (%) – 161/240 (67.1)
Erosive disease, n (%) – 149/229 (65.1)
Response during pregnancy, n (%) – 72/137 (52.6)
Flare during postpartum period, n (%) – 72/232 (31.0)
Disease activity score [DAS28(3)-CRP] at first 
trimester of pregnancy, mean (SD)
– 3.6 (1.1)
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With an added random intercept per individual, glycan 
variables were used as outcome variable and time point clas-
sification as predictor variable (model: glycosylation ~ β1·time 
point) (Table S4 in Supplementary Material). The effect of RA 
(healthy = 0; RA = 1) on glycosylation was modeled by applying 
a random intercept for all time points, using glycosylation as 
outcome variable and RA as predictor variable (model: glyco-
sylation  ~  β1·RA) (Table S5 in Supplementary Material). The 
effect of DAS28(3)-CRP on glycosylation was modeled by either 
having a random intercept per time point (to analyze between 
individuals) or a random intercept per individual (to analyze 
within individuals), using glycosylation as outcome variable 
and DAS28(3)-CRP as predictor variable [model: glycosyla-
tion ~ β1·DAS28(3)-CRP] (Table S6 in Supplementary Material).
To validate associations between glycosylation and disease 
activity during pregnancy, the difference in DAS28(3)-CRP 
[ΔDAS28(3)-CRP] and glycosylation (Δglycosylation) was 
established between the first trimester and third trimes-
ter of pregnancy (third trimester  −  first trimester). The 
association between these was established by linear regres-
sion [Δglycosylation  ~  β1·ΔDAS28(3)-CRP] (Table S7 in 
Supplementary Material). This process was similarly performed 
for the determination of the relationship between ΔDAS28(3)-
CRP and Δglycosylation during the postpartum period, which was 
established between the third trimester of pregnancy and 12 weeks 
postpartum time point (12 weeks postpartum − third trimester). 
The time point at 12 weeks postpartum was chosen for the calcula-
tion because it displayed the highest disease activity after delivery, 
since most patients had already restarted anti-rheumatic therapy 
afterward.
Throughout the study, the Benjamini–Hochberg procedure was 
employed to control for multiple testing, which, under a study-wide 
false discovery rate of 5%, resulted in a significance threshold of 
α = 3.03 × 10−2 (Table S8 in Supplementary Material) (37).
resUlTs
To explore the association between serum protein N-glycosylation 
and improvement of RA disease activity during pregnancy, we 
investigated by MALDI-TOF-MS the TSNG of 285 pregnancies 
embedded in the PARA study (characteristics of the study popu-
lation can be found in Table 1, medication details in Table 2) 
(31). This MS methodology allowed us to obtain information on 
78 glycan compositions (Figure  2; Table S1 in Supplementary 
Material), including discrimination between sialic acid linkage 
isomers, and to calculate biologically relevant ratios between 
subsets of glycans in the form of 91 derived traits (Table S2 in 
Supplementary Material) (29). Data quality was confirmed by 
the repeated measurement of a standard sample (Figure S1 and 
Table S3 in Supplementary Material).
Pregnancy-associated glycosylation 
changes
The association of pregnancy and the postpartum period with 
serum protein N-glycosylation was established by mixed linear 
regression. Within individuals, comparison was made between 
the first and third trimester (representative of pregnancy; respec-
tively, coded 0 and 1; adjusted for individual), third trimester 
and 6  weeks postpartum, and third trimester and 26+  weeks 
postpartum (Table S4 in Supplementary Material).
With progression of pregnancy, a marked alteration in overall 
number of antennae per N-glycan was observed (Figure 3, top 
row). During pregnancy, within the complex type glycans (C), 
the relative abundance of tri- and tetraantennary N-glycans 
(CA3, CA4) showed to increase at the expense of diantennary 
species (CA2) (βCA2  =  −1.05 SE  ±  0.06; βCA3  =  1.08  ±  0.06; 
βCA4 =  0.70 ±  0.06), followed by a slow recovery after delivery 
(βCA2 = 0.94 ± 0.07; βCA3 = −0.98 ± 0.07; βCA4 = −0.56 ± 0.08; 
Table S4 in Supplementary Material).
For the serum N-glycosylation characteristics likely originat-
ing from the Fc portion of IgG (diantennary N-glycans without 
sialylation; A2S0) (15, 26), we confirmed with progressing preg-
nancy a decrease in fucosylation (A2S0F, βA2S0F = −0.59 ± 0.05) 
and increase in galactosylation (A2FS0G, βA2FS0G = 0.59 ± 0.04), 
both rapidly reversing after delivery (βA2S0F  =  0.67  ±  0.04; 
βA2FS0G = −0.81 ± 0.04) (Figure 3, bottom row).
For the serum N-glycosylation characteristics likely originat-
ing for a large part from IgG-Fab, IgM, and IgA (fucosylated 
FigUre 2 | Comparison of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry spectra obtained from released N-glycans from serum 
proteins after linkage-specific sialic acid esterification and HILIC enrichment. The shown spectra are derived from an individual with rheumatoid arthritis who has 
been diagnosed with ACPA and RF, and has been classified as a responder by the EULAR response criteria. Notable differences between the first trimester (top) and 
third trimester (bottom) spectra include galactosylation (e.g., between m/z 1,485.5, 1,647.6, and 1,809.6), antennarity (e.g., m/z 2,940.1 vs. 2,301.8), α2,3-linked 
sialylation (e.g., m/z 2,255.8 vs. 2,301.8), and α2,6-linked sialylation (e.g., m/z 1,982.7 vs. 2,301.8).
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diantennary N-glycans with sialylation; A2FS) (15, 26), we observed 
a decrease in bisection with trimester progression (A2FSB, 
βA2FSB = −0.56 ± 0.04) and a rapid return to pre-pregnancy levels 
at 6 weeks postpartum (βA2FSB = 1.11 ± 0.03).
Notably, whereas α2,6-linked sialylation remained relatively 
stable throughout pregnancy (Figure 4, bottom row), a drastic 
increase of α2,3-linked sialylation (e.g., per galactose on di- or tri-
antennary glycans, respectively, A2GL and A3GL) was observed 
up to the third trimester (βA2GL = 1.11 ± 0.05; βA3GL = 1.16 ± 0.05), 
followed by a rapid return to baseline levels at the first time 
point after delivery (βA2GL = −1.19 ± 0.05; βA3GL = −1.42 ± 0.04) 
(Figure 4, top row).
Differences between healthy and ra
By mixed linear regression, glycosylation values were com-
pared between individuals with RA and controls (healthy = 0, 
RA  =  1; adjusted for pregnancy) (Table S5 in Supplementary 
Material). For immunoglobulin type glycosylation, we observed 
in RA a lower galactosylation (A2FS0G, βA2FS0G = −0.44 ± 0.07), 
higher bisection (A2FS0B, βA2FS0B = 0.55 ± 0.08), and a higher 
sialylation per galactose (A2FGS, βA2FGS  =  0.75  ±  0.08). In 
addition, differences were found in several non-fucosylated 
diantennary traits (higher A2F0G, A2F0GS, and A2GE, lower 
A2F0B, A2F), all mainly driven by elevated levels of H5N4E2 
(βH5N4E2 = 0.97 ± 0.07) in RA patient serum. For tri- and tetraan-
tennary N-glycosylation, we observe with RA a higher fuco-
sylation (e.g., A3F, βA3F = 0.34 ± 0.08; A4F, βA4F = 0.56 ± 0.08) 
particularly within species with α2,3-linked sialylation (A3LF, 
βA3LF  =  0.35  ±  0.08; A4LF, βA4LF  =  0.58  ±  0.08), suggesting an 
increase in sialyl-Lewis X/A.
association of glycosylation with 
Das28(3)-crP
In addition, we compared by mixed linear regression the asso-
ciation of glycosylation with RA disease activity, as assessed by 
DAS28(3)-CRP, both between and within individuals with RA 
(respectively, adjusted for time point and individual) (Figure 
S2 and Table S6 in Supplementary Material). The increase in 
DAS28(3)-CRP associated with both the decrease in IgG-Fc-type 
galactosylation (e.g., A2S0G, βA2S0G  =  −0.34  ±  0.02) and the 
decrease in fucosylation of non-α2,3-sialylated triantennary spe-
cies (A3L0F, βA3L0F = −0.13 ± 0.03). Increasing with DAS28(3)-
CRP were the bisection of IgG-Fc-type glycans (A2F0S0B, 
βA2F0S0B = 0.25 ± 0.03) as well as the sialylation and fucosylation of 
FigUre 3 | Overall glycosylation changes throughout pregnancy and the postpartum period shown in boxplots. Displayed are the glycan traits related to antennarity 
(top row), and the glycosylation traits likely to be of immunoglobulin origin (bottom row) (15, 26). Depicted are healthy controls (in white) and patients with 
rheumatoid arthritis (RA) (in gray) at preconception (pc), trimesters 1 through 3 (tm1, tm2, tm3), 6 weeks postpartum (pp1), 12 weeks postpartum (pp2), and 
26+ weeks postpartum (pp3). CA2, diantennary species within complex type; CA3, triantennary species within complex type; CA4, tetraantennary species within 
complex type; A2S0F, fucosylation of non-sialylated diantennary species; A2FS0G, galactosylation of non-sialylated fucosylated diantennary species; A2FSB, 
bisection of sialylated fucosylated diantennary species. Red brackets indicate statistically significant findings between time points (horizontal), or between healthy 
individuals and RA patients (vertical).
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tri- and tetraantennary species (e.g., A3FGS, βA3FGS = 0.26 ± 0.02; 
A4F, βA4F = 0.13 ± 0.03; A4GS, βA4GS = 0.17 ± 0.02). Glycosylation 
features associating with DAS28(3)-CRP only within (and not 
between) individuals throughout pregnancy were the fucosylation 
of (α2,6-)sialylated diantennaries (A2SF, βA2SF  =  −0.12  ±  0.02) 
and α2,6-sialylation of triantennary non-fucosylated species 
(A3F0GE, βA3F0GE = 0.14 ± 0.02).
association of glycosylation with  
the improvement of Das28(3)-crP  
during Pregnancy
Finally, between trimesters 1 and 3 (response timeframe) as well as 
between trimester 3 and 12 weeks postpartum (flare timeframe), 
we employed linear regression to confirm the within-individual 
association of DAS28(3)-CRP [ΔDAS28(3)-CRP] with glycosyla-
tion (Δglycosylation) (Table S7 in Supplementary Material). In 
both timeframes, ΔDAS28(3)-CRP showed a negative associa-
tion with the Δgalactosylation of IgG-Fc type species (ΔA2S0G, 
responder, βΔA2S0G = −0.29 ± 0.07; flare, βΔA2S0G = −0.35 ± 0.07; 
ΔA2FS0G, responder, βΔA2FS0G = −0.29 ± 0.07; flare, ΔA2FS0G; 
βΔA2FS0G  =  −0.33  ±  0.07), whereas the sialylation of trianten-
nary fucosylated species showed in both cases a positive 
association (ΔA3FGS, responder, βΔA3FGS  =  0.26  ±  0.07; flare, 
βΔA3FGS = 0.35 ± 0.07) (Figure 5). The flare timeframe addition-
ally showed a positive association of ΔDAS28(3)-CRP with the 
(α2,6)-sialylation of (fucosylated) diantennary glycans (ΔA2GE, 
βΔA2GE = 0.27 ± 0.07; ΔA2FGS, βΔA2FGS = 0.24 ± 0.07).
FigUre 4 | Sialylation changes throughout pregnancy and the postpartum period shown in boxplots. Whereas α2,3-linked sialylation (L) displays the most 
prominent change throughout pregnancy (top row), α2,6-linked sialylation shows the most distinction between patients and controls (bottom row). Separation is 
made between pregnancies of patients with rheumatoid arthritis (RA) (in gray) and healthy controls (in white). A2GL, α2,3-linked sialylation per galactose of 
diantennary species; A3GL, α2,3-linked sialylation per galactose of triantennary species; A4GL, α2,3-linked sialylation per galactose of tetraantennary species; 
A2GE, α2,6-linked sialylation per galactose of diantennary species; A3GE, α2,6-linked sialylation per galactose of triantennary species; A4GE, α2,6-linked sialylation 
per galactose of tetraantennary species. Red brackets indicate statistically significant findings between time points (horizontal), or between healthy individuals and 
RA patients (vertical).
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DiscUssiOn
The decrease of RA disease activity during pregnancy and the 
flare following delivery are reproducible clinical observations 
that are mechanistically poorly understood (8–10). To expand 
our understanding of protein glycosylation that associates with 
RA disease activity, we studied the total serum N-glycosylation 
changes occurring throughout pregnancy and the postpartum 
period of 253 pregnancies of patients with RA, along with 32 
control pregnancies.
interpretation of glycomics Data
To interpret the information contained in this study, several 
aspects of our MALDI-TOF-MS analysis need to be kept in 
mind. First, MS assesses glycan chemical compositions and 
not structures, although sialic acid linkage information is 
provided by the employed derivatization technique (29). 
Other structural characteristics are presumed based on a wide 
array of literature on biosynthetic pathways, and on experi-
ments with enzymatic digestion, nuclear magnetic resonance 
spectroscopy, and MS fragmentation (12, 15, 38–40). Second, 
the changes observed in the released N-glycan samples could 
have originated not only from changes in the glycosylation 
of proteins but also from changes in the abundance of those 
glycoproteins. Derived traits have been constructed to reflect 
differences in biosynthesis, and our current day understand-
ing of the relative contribution of specific glycoproteins and 
tissues to the serum N-glycome (15, 26). Third, the mass 
spectrometric analysis did not provide quantitative ratios of 
N-glycosylation, but the direction and magnitude of observed 
changes is expected to be biologically representative, as sug-
gested by method comparisons (41).
FigUre 5 | The relation between changing rheumatoid arthritis disease activity [ΔDAS28(3)-CRP] and changing glycosylation. Distinction is made between the 
timeframes to assess responder status (the change between first and third trimester; top row) and flare status (the change between third trimester and 12 weeks 
postpartum; bottom row). ΔA2S0G, the change in galactosylation per antenna of diantennary non-sialylated species; ΔA2FS0G, the change in galactosylation of 
diantennary fucosylated non-sialylated species; ΔA3FGS, the change in sialylation per galactose of triantennary fucosylated species. The significance of the models 
(p) arrives from linear regression, the correlation coefficients (r) from Pearson correlation.
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In addition, it has to be noted that the clinical associations 
found in the study may, in part, originate from treatment differ-
ences between individuals during the study period. For example, 
methotrexate treatment typically only starts after delivery, 
potentially influencing the time point comparisons. However, 
this confounding effect is expected to be limited due to the 
relatively low number of individuals undergoing the treatment. 
Details on the medication can be found in Table 2.
glycosylation changes with Pregnancy
Previously, we found glycosylation changes throughout healthy 
pregnancies, and have in RA patients studied the specific 
glycosylation of IgG-Fc throughout pregnancy (20, 21, 27, 
28, 42, 43). In the current study, the first application of a similar 
MALDI-MS approach with automated sample preparation, we 
achieved the analysis of the total serum N-glycosylation through-
out the pregnancies of both healthy controls and RA patients, in 
total leading to the analysis of 1,770 clinical samples (30). Since 
the current cohort also contains the control individuals (without 
RA) from prior studies, these previous results were confirmed, 
but we could also for the first time show that comparable TSNG 
changes can be observed in RA patients.
As such, we detected with the progression of pregnancy an 
increase of galactosylation (A2FS0G) as prior reported for the 
Fc part of IgG, as well as a decrease in bisection (A2FSB) (18, 
20, 21). Additionally, we observed with pregnancy an overall 
increase in glycan branching (from CA2 to CA3 and CA4) and 
an increase of α2,3-linked sialylation (L, in part at the expense of 
9
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α2,6-sialylation, E). In all cases, the postpartum period led to the 
return to the values before or at the beginning of pregnancy. The 
increased branching observed in the TSNG could have originated 
from the abundance and antennarity of acute-phase proteins such 
as alpha-1-acid glycoprotein, for which an increased serum level 
and N-glycan branching has been reported with pregnancy (24, 
25). On the other hand, we did not observe the decrease in fuco-
sylation reported for the same protein, potentially obscured by the 
increased fucosylation of other proteins, and have yet to identify 
the source of the substantial increase of α2,3-linked sialylation 
up to the third trimester. In literature, it has been reported that 
IgG and alpha-1-acid glycoprotein glycosylation may be affected 
by estrogens (44, 45), known to change significantly throughout 
pregnancy (46), and it is conceivable that other proteins within 
the TSNG are under similar high-level control.
glycosylation Differs between ra  
Patients and healthy controls
The total serum N-glycosylation changes with pregnancy showed 
remarkably comparable between RA patients and healthy con-
trols, but baseline differences could be detected. For example, RA 
patients displayed a lower degree of IgG-Fc-type galactosylation 
and higher bisection when compared to controls (A2FS0G, 
A2FS0B). A decreased IgG-Fc galactosylation and increased 
bisection are well-known to associate with a variety of inflamma-
tory conditions, including RA, inflammatory bowel disease, and 
aging (18, 47, 48), and the same glycosylation phenotypes appear 
detectable in our TSNG study as well (20, 21). The mechanisms 
by which IgG-Fc glycosylation may affect inflammatory processes 
remain for a large part to be elucidated, but increased galactosyla-
tion and decreased fucosylation have been implicated in increased 
FcγRIIa and FcγRIIIa binding and antibody-dependent cellular 
cytotoxicity (49–51).
Furthermore, RA patients showed in our study a higher α2,6-
sialylation and lower fucosylation of diantennary glycans (A2GE, 
A2F) compared to healthy controls, mainly driven by the N-glycan 
composition H5N4E2, as well as a substantially higher (multi-)
fucosylation of tri- and tetraantennary glycans [A3F(a), A4F(a)]. 
The increased A3/A4 fucosylation strongly suggests the upregula-
tion of sialyl-Lewis X, which has been reported with inflamma-
tory arthritis for several acute-phase proteins, e.g., alpha-1-acid 
glycoprotein, haptoglobin, alpha-1-antichymotrypsin, and trans-
ferrin (52–56). The sialyl-Lewis X on glycans is known to bind to 
E-selectin, an inducible receptor expressed by endothelial cells 
(16). This interaction is implicated in the homing of immune cells 
to a site of inflammation (57), as well as cancer metastasis (58), 
and may play a role in RA as well. For instance, the alpha-1-acid 
glycoprotein observed within RA synovial fluid is thought to be 
of hepatic origin (59), meaning its circulatory variant might make 
use of a glycan-mediated mechanism for transportation toward 
the inflamed synovial tissue.
glycosylation associates with  
ra Disease activity
Next to a negative association with the galactosylation of IgG-
Fc-type N-glycans, we additionally report a positive association 
between (Δ)DAS28(3)-CRP and the sialylation of triantennary 
fucosylated glycans (A3FGS), notably of the α2,6-linked variety. 
This is in contrast to the TSNG changes throughout pregnancy, 
which shows marked increase of α2,3-linked sialylation but not an 
association with disease activity. A recent study, which compared 
total plasma N-glycosylation with the levels of various metabolic 
and inflammatory markers, has indicated a link between A3FGS 
and CRP, suggesting that the CRP component of DAS28(3)-CRP 
may in part be responsible for the association found within the 
current study (60). While the protein source of A3FGS remains 
unknown, future studies will have to reveal its biomarker potential 
and facilitate our understanding of RA disease severity.
summary
To summarize, by performing MS-based total serum protein 
N-glycosylation analysis we detected (1) changes in protein 
glycosylation throughout pregnancy, (2) glycosylation differences 
between healthy individuals and RA patients, and (3) glycosyla-
tion traits coinciding with the pregnancy-associated changes in 
RA disease activity. While we confirmed in serum the IgG glyco-
sylation phenotypes that were prior reported to associate with RA 
disease activity, our glycomics approach has additionally allowed 
the detection of changes that are presumably independent from 
IgG, namely, the sialylation of fucosylated triantennary N-glycans 
(A3FGS).
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